Also Known As
NS2330 · TE
Overview
Tesofensine is an oral serotonin-norepinephrine-dopamine reuptake inhibitor originally developed for Parkinsons and Alzheimers. Now investigated for obesity treatment. Produces significant weight loss (10-12kg in trials).
Mechanism of Action
Inhibits reuptake of serotonin, norepinephrine, and dopamine. Reduces appetite and may increase resting energy expenditure. Metabolized by CYP3A4 to active metabolite M1.
Quick Reference
Notes
Very long half-life (~220 hours). Once daily dosing. Phase III trials for obesity ongoing. Not FDA approved.
Dosing Protocol
Pharmacokinetics
Administration
Special Instructions
Very long half-life (9+ days) - once daily dosing. Start at lowest dose (0.25mg). Weight loss effects take 2-4 weeks to manifest. Steady state reached in ~6 weeks. NOT FDA approved.
Warnings
Contraindications
Drug Interactions
Possible Side Effects
Legal & Regulatory
Pregnancy
Molecular Data
No sources available yet.
Related Peptides
No community data available yet. Be the first to add this peptide to your inventory!